Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

126 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether 4 weeks of treatment with aprepitant will improve nausea as compared with placebo in patients with symptoms of chronic nausea and vomiting of presumed gastric origin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

NCT00888329

Postoperative Nausea and Vomiting

TERMINATED PHASE4

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

NCT00956215

Nausea Vomiting

COMPLETED NA

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

NCT02970968

Gastroparesis

COMPLETED PHASE2

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

NCT06543966

Post-operative Nausea and Vomiting (PONV)

NOT_YET_RECRUITING PHASE3

Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

NCT00970905

Nausea Vomiting

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

APRON is a multicenter, randomized, double-masked, placebo controlled trial of 4 weeks of treatment with aprepitant or placebo for patients with symptoms of gastroparesis and related disorders. Screening for eligibility and collection of baseline data will span up to 4 weeks after obtaining informed consent and registration. Eligible patients will consist of patients with symptoms of gastroparesis and will be randomized to either aprepitant (125 mg per day) or placebo for 4 weeks.

The symptoms will be measured with the Gastroparesis Cardinal Symptom Index Daily Diary (GCSIDD) for one week at baseline and for four weeks after randomization. In addition, the nausea symptom will be measured daily on a 0 to 100 mm visual analog scale (VAS) for one week at baseline and daily for four weeks after randomization. There will be a 2 week washout period at the end of the treatment to ensure patient safety following the end of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroparesis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aprepitant

Aprepitant 125 mg per day

Group Type ACTIVE_COMPARATOR

Aprepitant

Intervention Type DRUG

Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks

Aprepitant-placebo

Placebo aprepitant 125mg per day

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aprepitant

Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks

Intervention Type DRUG

Placebo

Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Emend

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older at registration
* Gastric emptying scintigraphy within 2 years of registration
* Normal upper endoscopy or upper GI series within 2 years of registration
* Symptoms of chronic nausea or vomiting compatible with gastroparesis or other functional gastric disorder for at least 6 months (does not have to be contiguous) prior to registration with Gastroparesis Cardinal Symptom Index (GCSI) score of greater than or equal to 21
* Significant nausea defined with a visual analog scale (VAS) score of greater than or equal to 25 mm on a 0 to 100 mm scale

Exclusion Criteria

* Another active disorder which could explain symptoms in the opinion of the investigator
* Use of narcotics more than 3 days per week
* Significant hepatic injury as defined by significant alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations of greater than 2x the upper limit of normal (ULN) or a Child-Pugh score of 10 or greater
* Contraindications to aprepitant such as hypersensitivity or allergy
* Concurrent use of warfarin, pimozide, terfenadine, astemizole, or cisapride
* Pregnancy or nursing
* Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study
* Failure to give informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No